Insys Therapeutics Revenue 2006-2018 | INSY
Insys Therapeutics revenue from 2006 to 2018. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
| Insys Therapeutics Annual Revenue (Millions of US $) |
|
|---|---|
| 2017 | $141 |
| 2016 | $242 |
| 2015 | $330 |
| 2014 | $219 |
| 2013 | $99 |
| 2012 | $15 |
| 2011 | $0 |
| 2009 | $0 |
| 2008 | $0 |
| 2007 | $0 |
| 2006 | $0 |
| 2005 | $1 |
| Insys Therapeutics Quarterly Revenue (Millions of US $) |
|
|---|---|
| Q3 2018 | $18 |
| Q2 2018 | $23 |
| Q1 2018 | $24 |
| Q4 2017 | $31 |
| Q3 2017 | $31 |
| Q2 2017 | $43 |
| Q1 2017 | $36 |
| Q4 2016 | $55 |
| Q3 2016 | $58 |
| Q2 2016 | $69 |
| Q1 2016 | $60 |
| Q4 2015 | $94 |
| Q3 2015 | $89 |
| Q2 2015 | $80 |
| Q1 2015 | $68 |
| Q4 2014 | $63 |
| Q3 2014 | $58 |
| Q2 2014 | $56 |
| Q1 2014 | $42 |
| Q4 2013 | $40 |
| Q3 2013 | $29 |
| Q2 2013 | $19 |
| Q1 2013 | $11 |
| Q4 2012 | $5 |
| Q3 2012 | $5 |
| Q2 2012 | $4 |
| Q1 2012 | $2 |
| Q4 2011 | $0 |
| Q2 2010 | $0 |
| Q1 2010 | $0 |
| Q4 2009 | $0 |
| Q3 2009 | $0 |
| Q2 2009 | $0 |
| Q1 2009 | $0 |
| Q4 2008 | $0 |
| Q3 2008 | $0 |
| Q2 2008 | $0 |
| Q1 2008 | $0 |
| Q4 2007 | $0 |
| Q3 2007 | $0 |
| Q2 2007 | $0 |
| Q1 2007 | $0 |
| Q4 2006 | $-0 |
| Q3 2006 | $0 |
| Q2 2006 | $0 |
| Q1 2006 | $2 |
| Q4 2005 | $0 |
| Q3 2005 | $0 |
| Q2 2005 | $0 |
| Q1 2005 | $0 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.368B | $0.141B |
| Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray and Dronabinol SG capsule. Insys Therapeutics, Inc. is based in Phoenix, Arizona. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $132.164B | 26.13 |
| Medtronic (MDT) | Ireland | $123.923B | 18.53 |
| Stryker (SYK) | United States | $69.625B | 25.56 |
| Boston Scientific (BSX) | United States | $55.366B | 27.03 |
| Baxter (BAX) | United States | $39.075B | 24.08 |
| Zimmer Biomet Holdings (ZBH) | United States | $25.222B | 16.18 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.659B | 0.00 |
| ResMed (RMD) | United States | $14.394B | 27.30 |
| Canopy Growth (CGC) | Canada | $11.042B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.100B | 51.79 |
| Aurora Cannabis (ACB) | Canada | $7.040B | 50.36 |
| Hill-Rom Holdings (HRC) | United States | $6.974B | 21.57 |
| Perrigo (PRGO) | Ireland | $6.650B | 10.09 |
| Insulet (PODD) | United States | $5.226B | 0.00 |
| ICU Medical (ICUI) | United States | $5.189B | 28.91 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $4.539B | 0.00 |
| Haemonetics (HAE) | United States | $4.489B | 39.82 |
| Agios Pharmaceuticals (AGIO) | United States | $3.449B | 0.00 |
| Hutchison China MediTech (HCM) | China | $3.417B | 0.00 |
| Neogen (NEOG) | United States | $3.281B | 50.39 |
| NuVasive (NUVA) | United States | $3.013B | 28.03 |
| National Vision Holdings (EYE) | United States | $2.624B | 50.75 |
| Quidel (QDEL) | United States | $2.574B | 23.28 |
| Aphria (APHA) | $2.402B | 106.67 | |
| NxStage Medical (NXTM) | United States | $1.954B | 0.00 |
| AtriCure (ATRC) | United States | $1.279B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.231B | 17.70 |
| VAREX IMAGING (VREX) | United States | $1.198B | 23.45 |
| Cardiovascular Systems (CSII) | United States | $1.170B | 840.00 |
| HEXO (HEXO) | $1.156B | 0.00 | |
| MacroGenics (MGNX) | United States | $0.923B | 0.00 |
| Cerus (CERS) | United States | $0.878B | 0.00 |
| PetIQ (PETQ) | United States | $0.837B | 21.68 |
| Surmodics (SRDX) | United States | $0.766B | 111.39 |
| Evolus (EOLS) | United States | $0.747B | 0.00 |
| NanoString Technologies (NSTG) | United States | $0.719B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $0.713B | 22.07 |
| Meridian Bioscience (VIVO) | United States | $0.704B | 20.97 |
| OraSure Technologies (OSUR) | United States | $0.703B | 31.03 |
| Omeros (OMER) | United States | $0.688B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.625B | 20.05 |
| Quanterix (QTRX) | United States | $0.505B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $0.492B | 24.18 |
| Owens & Minor (OMI) | United States | $0.479B | 5.42 |
| TG Therapeutics (TGTX) | United States | $0.395B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.334B | 21.65 |
| BioLife Solutions (BLFS) | United States | $0.299B | 404.00 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.293B | 0.00 |
| Bovie Medical (APYX) | United States | $0.279B | 0.00 |
| Vapotherm (VAPO) | United States | $0.276B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.262B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.242B | 0.00 |
| Zynex (ZYXI) | United States | $0.165B | 15.97 |
| Surface Oncology (SURF) | United States | $0.150B | 0.00 |
| Fonar (FONR) | United States | $0.143B | 7.65 |
| Chembio Diagnostics (CEMI) | United States | $0.119B | 0.00 |
| Chimerix (CMRX) | United States | $0.101B | 0.00 |
| United-Guardian (UG) | United States | $0.091B | 18.98 |
| Female Health (VERU) | United States | $0.084B | 0.00 |
| InfuSystems Holdings (INFU) | United States | $0.081B | 0.00 |
| CAS Medical Systems (CASM) | United States | $0.070B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.063B | 17.33 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.062B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.056B | 0.00 |
| ImmuCell (ICCC) | United States | $0.038B | 0.00 |
| Neurotrope (NTRP) | United States | $0.034B | 0.00 |
| Senestech (SNES) | United States | $0.021B | 0.00 |
| Myomo (MYO) | United States | $0.016B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.013B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.013B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.011B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.010B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.007B | 13.57 |
